Azacitidine as a bridge to allogeneic hematopoietic cell transplantation in a pediatric patient with Fanconi anemia and acute myeloid leukemia |
| |
| Authors: | Hilda Ding Hasan Hashem Linda Cabral Hemalatha Rangarajan Ghada Abusin Hillard M. Lazarus Rolla Abu‐Arja |
| |
| Affiliation: | 1. Pediatric Hematology‐Oncology and Bone Marrow Transplantation, University Hospitals Rainbow Babies & Children's Hospital/Case Medical Center, Cleveland, OH, USA;2. Pediatric Hematology Oncology and Bone Marrow Transplant, Nationwide Children's Hospital, Columbus, OH, USA;3. Pediatric Hematology/Oncology and Bone Marrow Transplant, University of Iowa Children's Hospital, Iowa City, IA, USA;4. Department of Medicine‐Hematology and Oncology, University Hospitals Case Medical Center, Cleveland, OH, USA |
| |
| Abstract: | HCT is the definitive therapy for patients with FA and AML. Conventional cytotoxic agents cause potential DNA damage, and currently, there is no established regimen for these patients prior to HCT. A 13‐year‐old male with FA and refractory AML was given azacitidine, achieved morphologic remission and underwent HCT. At 95 days after HCT, he relapsed. Azacitidine along with DLI was used as first salvage therapy. Azacitidine was overall well tolerated with minimal side effects. In patients with AML and FA, azacitidine can be considered an alternative to conventional chemotherapy. |
| |
| Keywords: | acute myeloid leukemia azacitidine donor lymphocyte infusion Fanconi anemia hematopoietic cell transplant pediatric |
|
|
